Literature DB >> 2594203

SPECT bone scintigraphy of benign and malignant lesions of the spine.

B Nägele-Wöhrle1, O Nickel, K Hahn.   

Abstract

70 patients were examined with planar and SPECT bone scintigraphy. SPECT proved to be superior over planar bone scanning for imaging of traumatic, inflammatory, and malignant bone lesions. SPECT provides three-dimensional information and, therefore, delineates the exact location and extension of lesions. It also has a higher sensitivity than planar bone scintigraphy. The three-dimensional bone scan generates complementary diagnostic information which often facilitates an adequate therapy protocol.

Entities:  

Mesh:

Year:  1989        PMID: 2594203     DOI: 10.1007/bf01780839

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  6 in total

1.  [Clinical importance of emission-computed tomography of the skull in bone scintigraphy].

Authors:  H König; U Feine; W Müller-Schauenburg
Journal:  Rofo       Date:  1985-10

2.  [Optimization of conditions for detecting density variations in focal activity in SPECT using the rotating gamma camera. Model calculations, phantom measurements and clinical applications].

Authors:  P Wust; G Golde; R Schneider; W Fiegler; J P Hedde
Journal:  Rofo       Date:  1986-06

3.  [Single photon emission computed tomography of patients with benign and malignant spinal diseases].

Authors:  E U Bieler; K Fox; E Rummeny; P Pfannenstiel
Journal:  Rofo       Date:  1986-08

Review 4.  Bone SPECT.

Authors:  B D Collier; R S Hellman; A Z Krasnow
Journal:  Semin Nucl Med       Date:  1987-07       Impact factor: 4.446

5.  The application of single photon emission computed tomography to the diagnosis of ankylosing spondylitis of the spine.

Authors:  H Jacobsson; S A Larsson; L Vestersköld; N Lindvall
Journal:  Br J Radiol       Date:  1984-02       Impact factor: 3.039

6.  Lesion detection with single-photon emission computed tomography (SPECT) compared with conventional imaging.

Authors:  R J Jaszczak; F R Whitehead; C B Lim; R E Coleman
Journal:  J Nucl Med       Date:  1982-02       Impact factor: 10.057

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.